<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Lincomycin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01627</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01627/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01627/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01627.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01627.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01627.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01627.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01627.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01627">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>LCM</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lincomycine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Lincomycin hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000109/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000109/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: POUMFISTNHIPTI-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 442.190435259</li>
              <li>Average Mass: 442.998</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000109">DBSALT000109</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Lincobect</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lincocin</td><td>Upjohn</td></tr><tr><td>Lincorex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/protein-synthesis-inhibitors">Protein Synthesis Inhibitors</a></li>
<li><a href="/mesh/antibiotics">Antibiotics</a></li></ul></td></tr><tr><th>CAS number</th><td>154-21-2</td></tr><tr><th>Weight</th><td>Average: 406.537<br>Monoisotopic: 406.21375752</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>34</sub>N<sub>2</sub>O<sub>6</sub>S</td></tr><tr><th>InChI Key</th><td>OJMMVQQUTAEWLP-ISVUEQNNSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11?,12-,13+,14-,15-,16-,18-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]1(O[C@]([H])([C@H](NC(=O)C2C[C@@H](CCC)CN2C)[C@@H](C)O)[C@H](O)[C@H](O)[C@H]1O)SC</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB01627.gif?1265922773">show</a>(7.07 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Alpha Amino Acid Amides</td></tr><tr><th>Alternative parents</th><td>Pyrrolidinecarboxamides; Oxanes; Dithioacetals; Secondary Alcohols; Secondary Carboxylic Acid Amides; Tertiary Amines; 1,2-Diols; Polyamines; Enolates; Ethers; Carboxylic Acids; Thioethers</td></tr><tr><th>Substituents</th><td>pyrrolidine carboxylic acid or derivative; pyrrolidine-2-carboxamide; oxane; pyrrolidine; thioacetal; polyol; 1,2-diol; tertiary amine; carboxamide group; secondary alcohol; secondary carboxylic acid amide; ether; polyamine; enolate; carboxylic acid; thioether; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the alpha amino acid amides. These are amide derivatives of alpha amino acids.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Lincomycin is an antibiotic used in the treatment of staphylococcal, streptococcal, and <i>Bacteroides fragilis</i> infections.</td></tr><tr><th>Pharmacodynamics</th><td>Lincomycin is a lincosamide antibiotic that comes from the yeast <i>Streptomyces lincolnensis</i>. Lincomycin has been shown to be active in vitro against the following microorganisms: Aerobic gram-positive cocci: <i>Streptococcus pyogenes</i> and <i>Viridans group streptococci</i>; Aerobic gram-positive bacilli: <i>Corynebacterium diphtheriae</i>; Anaerobic gram-positive non-sporeforming bacilli: <i>Propionibacterium acnes</i>; Anaerobic gram-positive sporeforming bacilli: <i>Clostridium tetani</i> and <i>Clostridium perfringens</i>.</td></tr><tr><th>Mechanism of action</th><td>Lincomycin inhibits protein synthesis in susceptible bacteria by binding to the 50 S subunits of bacterial ribosomes and preventing peptide bond formation upon transcription. It is usually considered bacteriostatic, but may be bactericidal in high concentrations or when used against highly susceptible organisms.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed from the gastrointestinal tract following oral administration. Approximately 20 to 30% absorbed orally in fasting state; absorption decreased when taken with food.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Protein binding decreases with increased plasma concentrations. Range, 28 to 86% (average, 70 to 75%). Albumin is not thought to be the primary binding component.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Presumed hepatic, however metabolites have not been fully characterized.</p></td></tr><tr><th>Route of elimination</th><td>Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 3 percent). Tissue level studies indicate that bile is an important route of excretion.</td></tr><tr><th>Half life</th><td>The biological half-life after intramuscular or intravenous administration is 5.4 &#177; 1.0 hours. The serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function compared to patients with normal renal function. In patients with abnormal hepatic function, serum half-life may be twofold longer than in patients with normal hepatic function. </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.5937</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9659</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7945</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6755</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5633</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8868</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8417</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8837</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6389</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9222</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9269</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9203</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9342</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9563</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7696
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9482
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9622
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5777 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9847
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7163
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pharmacia and upjohn co</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bimeda.com">Bimeda Inc.</a></li>
<li>Carlisle Laboratories Inc.</li>
<li><a href="http://www.clintpharmaceuticals.com">Clint Pharmaceutical Inc.</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li>Keene Pharmaceuticals Inc.</li>
<li><a href="http://www.llorenspharm.com">Llorens Pharmaceutical</a></li>
<li>Martin Surgical Supply</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li>Nord Ost Corp.</li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Raz Co. Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01370">Aluminium</a></td><td>The aluminium salt decreases the absorption of lincosamides</td></tr><tr><td><a href="/drugs/DB00732">Atracurium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01574">Attapulgite</a></td><td>The aluminium salt decreases the absorption of lincosamides</td></tr><tr><td><a href="/drugs/DB01135">Doxacurium chloride</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Possible antagonism of action with this combination.</td></tr><tr><td><a href="/drugs/DB01575">Kaolin</a></td><td>The aluminium salt decreases the absorption of lincosamides</td></tr><tr><td><a href="/drugs/DB01336">Metocurine</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01226">Mivacurium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01337">Pancuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01338">Pipecuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00728">Rocuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00202">Succinylcholine</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01199">Tubocurarine</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01339">Vecuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take on an empty stomach, food decreases absorption.</li></ul></td></tr></tbody></table>